Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tonix Pharmaceuticals Holding - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TNXP
Nasdaq
8731
https://www.tonixpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tonix Pharmaceuticals Holding
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
- Apr 29th, 2024 1:00 pm
TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025…
- Apr 29th, 2024 11:31 am
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
- Apr 24th, 2024 12:00 pm
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Apr 1st, 2024 8:15 pm
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
- Mar 28th, 2024 1:32 pm
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
- Mar 25th, 2024 12:00 pm
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
- Mar 24th, 2024 8:05 pm
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
- Mar 21st, 2024 12:00 pm
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
- Mar 20th, 2024 12:00 pm
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
- Mar 19th, 2024 12:00 pm
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
- Mar 12th, 2024 12:00 pm
TNXP: Tonmya™ May Launch Alongside Another New Fibromyalgia Treatment…
- Mar 12th, 2024 11:34 am
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
- Mar 11th, 2024 12:00 pm
New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT
- Mar 7th, 2024 2:37 pm
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
- Mar 7th, 2024 1:00 pm
Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia
- Mar 6th, 2024 1:00 pm
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
- Mar 5th, 2024 1:00 pm
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
- Feb 29th, 2024 1:00 pm
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
- Feb 28th, 2024 1:00 pm
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China
- Feb 27th, 2024 1:00 pm
Scroll